ArticleBlood advances2019
Invariant phenotype and molecular association of biallelic
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 64 citations in OpenAlex.
- Prognostic implications ofBlood neoplasia · 2026Article
- Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s).Leukemia · 2026Article
- Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.Blood cancer journal · 2026Article
- [Molecular and clinical characteristics and prognosis of myelodysplastic neoplasms with biallelic TET2 inactivation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Harnessing genomics for early cancer detection, risk stratification and prevention.Nature genetics · 2026Review
- Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.Journal of hematopathology · 2026Article
- Article
- Article
- [Myelodysplastic neoplasms with acute myeloid leukemia-like mutations: clinical features, molecular profiles, and prognosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Application of the International Working Group MDS molecular taxonomy classes to a single institution cohort.Blood neoplasia · 2025Article
- Review
- Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.Blood advances · 2025Article
- Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.Current hematologic malignancy reports · 2025Review
- Myeloid Neoplasms With Oligomonocytosis Exhibit Heterogenous Pathologic and Genetic Features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Article
- Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia.Annals of hematology · 2025Article
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective.Genes · 2025Review
- Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management.Leukemia · 2025Review
- Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes.Leukemia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 3 countries.
Hassan AwadaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Yasunobu NagataDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Abhinav GoyalDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Mohammad F AsadDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Bhumika PatelLeukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and.
Cassandra M HirschDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Teodora KuzmanovicDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Yihong GuanDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Bartlomiej P PrzychodzenDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Mai AlyDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Vera AdemaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Wenyi ShenDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Louis WilliamsDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Aziz NazhaLeukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and.
Mohamed E AbazeedDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.ORCID 0000-0002-6614-4440
Mikkael A SekeresLeukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and.
Tomas RadivoyevitchDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; and.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Babal K JhaDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Lerner Research Institute.
Cerner (United States) · USCancer Institute (WIA) · INCleveland Clinic · USMunich Leukemia Laboratory (Germany) · DE
Funding
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MTherapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MNovel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4MRNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1MInvestigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9MNCI NIH HHS K12 CA076917NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
Abstract
Somatic
Indexed as
AdolescentAdultAgedAged, 80 and overDioxygenasesDNA-Binding ProteinsFemaleGene SilencingHumansMaleMiddle AgedMutationMyelodysplastic SyndromesPhenotypePrognosisProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.